Trying this for struggles with weight
Kelly Wilkinson/IndyStar
Sean Copeland works out at Exercise Inc., Wednesday, Jan. 10, 2024 in Greenwood. The 20-minute workout circuit once a week works with Copeland's use of the Eli Lilly drug Mounjaro to help with weight loss. The exercise helps him maintain muscle mass while losing weight.
Kelly Wilkinson/IndyStar
Seen through a variety of exercise machines, Sean Copeland works out at Exercise Inc., Wednesday, Jan. 10, 2024 in Greenwood. The 20-minute workout circuit once a week works with Copeland's use of the Eli Lilly drug Mounjaro to help with weight loss. The exercise helps him maintain muscle mass while losing weight.
Kelly Wilkinson/IndyStar
Sean Copeland, right, works out with Personal Fitness Coach Kyle Morrison at Exercise Inc., Wednesday, Jan. 10, 2024 in Greenwood. The 20-minute workout circuit once a week works with Copeland's use of the Eli Lilly drug Mounjaro to help with weight loss. The exercise helps him maintain muscle mass while losing weight.
Kelly Wilkinson/IndyStar
Sean Copeland works out at Exercise Inc., Wednesday, Jan. 10, 2024 in Greenwood. The 20-minute workout circuit once a week works with Copeland's use of the Eli Lilly drug Mounjaro to help with weight loss. The exercise helps him maintain muscle mass while losing weight.
Kelly Wilkinson/IndyStar
Sean Copeland, left, works out with Personal Fitness Coach Kyle Morrison at Exercise Inc., Wednesday, Jan. 10, 2024 in Greenwood. The 20-minute workout circuit once a week works with Copeland's use of the Eli Lilly drug Mounjaro to help with weight loss. The exercise helps him maintain muscle mass while losing weight.
Kelly Wilkinson/IndyStar
Sean Copeland works out at Exercise Inc., Wednesday, Jan. 10, 2024 in Greenwood. The 20-minute workout circuit once a week works with Copeland's use of the Eli Lilly drug Mounjaro to help with weight loss. The exercise helps him maintain muscle mass while losing weight.
Kelly Wilkinson/IndyStar
Sean Copeland works out with Personal Fitness Coach Kyle Morrison at Exercise Inc., Wednesday, Jan. 10, 2024 in Greenwood. The 20-minute workout circuit once a week works with Copeland's use of the Eli Lilly drug Mounjaro to help with weight loss. The exercise helps him maintain muscle mass while losing weight.
Kelly Wilkinson/IndyStar
Sean Copeland strains for the last reps as he works out at Exercise Inc., Wednesday, Jan. 10, 2024 in Greenwood. The 20-minute workout circuit once a week works with Copeland's use of the Eli Lilly drug Mounjaro to help with weight loss. The exercise helps him maintain muscle mass while losing weight.
Kelly Wilkinson/IndyStar
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
an hour ago
- Fast Company
Wegovy and Zepbound patients are resorting to these cost-saving measures to stay on the weight-loss drugs
Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but as more U.S. insurers restrict coverage people are trimming costs by stretching doses or forgoing expenditures like vacations to pay for the medication out of pocket. A half dozen doctors who spoke with Reuters said insurance coverage has tightened in 2025 as many employers drop it for the expensive GLP-1 drugs. While patients on these medications are counseled on proper diet and exercise, clinical trials show that people who stop taking these drugs are apt to regain weight. Novo Nordisk's Wegovy and Eli Lilly's Zepbound are weekly injections with U.S. insurer list prices of more than $1,000 a month. For customers willing to pay cash, both drugmakers will ship directly for $499 a month if refills are purchased at fixed intervals. 'A significant number of my patients now pay cash,' said Dr. Nidhi Kansal, an obesity specialist at Northwestern Medicine in Chicago. 'People find a way to scrounge up $6,000 a year, which sucks, because that's a vacation or two.' Subscribe to the Daily newsletter. Fast Company's trending stories delivered to you every day Privacy Policy | Fast Company Newsletters More than a billion people worldwide are obese, according to the U.N. World Health Organization, which has said the GLP-1 drugs could help end the obesity pandemic. 'A KIND OF PURGATORY' A tech industry job change for Yelena Kibasova, a 40-year-old who lives in the Minneapolis area, meant loss of coverage for her Zepbound prescription that helped her achieve and maintain a 150-pound (68-kg) weight loss. GLP-1 patient Yelena Kibasova, 40, poses in this undated handout picture. [Photo: @morethanmyweight/Handout via Reuters] 'My new company does not cover GLP-1s, so now I am in a kind of purgatory,' Kibasova said. 'I stopped doing my nails. I stopped doing my hair. Those things are not as important as me staying at a healthy weight.' The doctors interviewed by Reuters said patients once leery about long-term obesity treatment are now more comfortable staying on a drug. The doctors said that conversations about temporary use happen only when a patient is trying to lose a certain amount of weight for issues such as fertility treatment or an organ transplant. These obesity specialists said they are hopeful that competition will help bring down prices as new weight-loss options emerge, including new oral drugs that may be available next year. Lilly last week announced trial results for its easier-to-manufacture pill, which was shown to cut patient weight by 12.4%, a few percentage points less than injected drugs. The company hopes to launch it in August 2026. Kenneth Custer, Lilly's head of cardiometabolic health, told Reuters the pill is being tested in several settings, including as a maintenance therapy. Custer declined to comment on how it might be priced. MEDICATION FOR MAINTENANCE Dr. Anne Peters, an endocrinologist at Keck Medicine USC in Los Angeles, said it is important that patients who reach their weight-loss goal not stop a prescription 'cold turkey,' so the dose can be tapered down over several months. Peters said about a third of her patients are able to reduce their dose and maintain weight loss, while the rest need to stay on the medication. An analysis of U.S. pharmacy insurance claims found that nearly two-thirds of patients who started on Wegovy or Zepbound in 2024 were still on the medications a year later. advertisement Peters said she uses 'every technique in the book' to secure insurance coverage for patients, but noted that a growing number of plans no longer pay for the treatments, and patients have to pay out-of-pocket. U.S. pharmacies supply self-injection pens pre-loaded with doses of Wegovy or Zepbound. Lilly's direct-to-consumer service also offers vials. 'Some patients can stretch out the vials longer. Get 15 mg, and then give a 10 mg dose for instance,' Dr. Peters said, noting that the drug's instructions advise that such an approach should not be taken. Doses of 5 mg, 10 mg and 15 mg are recommended for weight-loss maintenance. Patients also are turning to lower-cost compounded versions of the GLP-1 drugs, or are even mixing them at home with raw ingredients, both of which Peters and other doctors advise against due to safety concerns. Dr. Angela Fitch, former president of the Centennial, Colorado-based Obesity Medicine Association and chief medical officer at online primary care provider Knownwell, said nobody wants to be on a medication, but patients who respond to a GLP-1 drug 'really don't want to go off of it when they recognize that it has such a value to them.' Both Wegovy and Zepbound were first launched, under the brand names Ozempic and Mounjaro, as diabetes treatments. The class has been linked to a range of benefits, including improved heart health and less sleep apnea. Fitch said the most common reason for her patients to stop taking a GLP-1 drug is loss of insurance coverage. She said her experience is that about 10% of patients are able to reach a target weight and maintain it without further treatment. 'We are in a dip where people are dropping coverage,' Fitch said, adding that the direct-to-consumer options are an 'upper-ish middle-class thing.' —Deena Beasley, Reuters
Yahoo
2 hours ago
- Yahoo
Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB
The Saudi Arabia Osteoporosis Drugs Market is projected to grow from US$ 210.89 million in 2024 to US$ 308.84 million by 2033, with a CAGR of 4.33% from 2025. Major growth drivers include an aging population, increasing osteoporosis rates, and favorable healthcare regulations. While bisphosphonates remain popular for their cost-effectiveness, biologics are expected to see the fastest growth. Government initiatives under Vision 2030 support local drug production and healthcare infrastructure, enhancing drug accessibility. However, challenges such as low adherence and rural access remain. Key market players include Amgen, Eli Lilly, and Pfizer. Saudi Arabian Osteoporosis Drugs Market Dublin, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Osteoporosis Drugs Market to Reach US$ 308.84 Million by 2033 - 4.33% CAGR Driven by Biologics and Aging Population" report has been added to Saudi Arabia Osteoporosis Drugs Market is expected to reach US$ 308.84 million by 2033 from US$ 210.89 million in 2024, with a CAGR of 4.33% from 2025 to 2033 Due to improved healthcare infrastructure, the Saudi Arabian market for osteoporosis medications is concentrated in urban areas like Riyadh, Jeddah, and Dammam, whereas rural areas have less access to experts, diagnostics, and treatment alternatives. Growing rates of osteoporosis, the quick uptake of biologics, and advantageous healthcare laws in a number of Saudi Arabian nations are the main causes of this expansion. While bisphosphonates continue to dominate in volume due to their cost effectiveness, the biologics segment is anticipated to grow at the quickest rate. Government programs under Vision 2030, which prioritize regional medication production and improved healthcare infrastructure, promote the pharmaceutical industry. Osteoporosis treatments are becoming more accessible and reasonably priced as a result of these initiatives, and both name brand and generic medications are essential in satisfying the rising calcitonin, parathyroid hormone analogs, selective estrogen receptor modulators (SERMs), and monoclonal antibodies are among the available treatments. Newer biologic medicines are steadily gaining traction because of their increased efficacy and better patient outcomes, even if bisphosphonates are still frequently administered. Despite progress, issues like poor drug adherence, low awareness in rural regions, and underdiagnosis still exist. Additionally, comprehensive nationwide screening programs and coordinated post fracture care are lacking. Reducing the long term economic cost of osteoporosis in the nation and improving treatment outcomes could be achieved by addressing these challenges through integrated care models, digital health technologies, and Factors Driving the Saudi Arabia Osteoporosis Drugs Market Growth Saudi Arabia's Aging Population Is GrowingBecause osteoporosis and aging are closely related, Saudi Arabia's aging population is a major factor driving up demand for osteoporosis medications. People are more susceptible to fractures, loss of bone density, and associated problems as they get older, especially those over?60. The need for long term therapeutic treatments as well as preventive measures is growing as a result of this demographic shift. More people are reaching the age range where osteoporosis becomes a major concern due to better healthcare and longer life expectancies. As a result, the incidence of osteoporosis is rising in areas with greater populations of elderly persons. In order to assist the aging population and lessen the health burden associated with fractures, this development emphasizes the urgent need for efficient drugs and healthcare Rates of Screening and DiagnosisEarly osteoporosis identification has increased throughout Saudi Arabia thanks to the availability of sophisticated diagnostic technologies including dual energy X ray absorptiometry (DEXA) and bone mineral density (BMD) scanning. These technologies are now widely used in hospitals and clinics, increasing screening accessibility for high risk populations, especially postmenopausal women. In order to encourage early testing and diagnosis, health authorities are aggressively promoting awareness and screening initiatives. Because of this, more people are being diagnosed with bone loss early on, when treatment can be most successful. The number of patients eligible for osteoporosis treatments has increased dramatically due to the increase in early detection, which has increased demand for pharmacological interventions and made it possible to control the condition more effectively over the long Initiated Medical ProgramsAs a national health issue, osteoporosis is being actively addressed by the Saudi Arabian government. It seeks to lower the frequency of fractures and enhance bone health outcomes through education programs, public health campaigns, and preventative measures. Osteoporosis screening and bone density monitoring are becoming more commonplace in national health programs, and access to therapies is being facilitated by drug reimbursement policies and subsidized treatment options. These programs are promoting earlier medical intervention and increasing treatment adherence. Additionally, by making strategic investments in public health, the government's Vision 2030 push for local pharmaceutical development and a larger healthcare infrastructure is bolstering the availability of osteoporosis medications and promoting long term market in the Saudi Arabia Osteoporosis Drugs Market Low Persistence and Adherence to TreatmentLow patient adherence and persistence with prescribed medication regimens is one of the main issues facing Saudi Arabia's osteoporosis management. A lack of immediate, apparent benefits, worries about long term health repercussions, or worries about adverse effects cause many patients to stop treatment too soon. Non-adherence is also influenced by cultural norms and a lack of knowledge about how osteoporosis progresses. Treatment results are harmed as a result, raising the risk of fractures and associated problems. Long term patient involvement is challenging for healthcare practitioners, particularly when patients need daily or weekly oral medication. Enhancing patient education, providing alternate dosage regimens, and incorporating follow up assistance may all contribute to increased adherence and improved population wide therapeutic Treatment Persistence and AdherencePoor patient perseverance and adherence to prescribed treatment regimens is one of the main issues facing osteoporosis care in Saudi Arabia. Due to worries about side effects, worries about long term health repercussions, or a lack of obvious, immediate advantages, many patients stop treatment too soon. Non-adherence is further exacerbated by cultural attitudes and a lack of knowledge regarding the progressive nature of osteoporosis. Treatment results suffer as a result, and the risk of fractures and associated complications rises. It can be challenging for healthcare professionals to stay in touch with patients over the long term, particularly when they need daily or weekly oral medication. Enhancing follow up assistance, providing alternate dose schedules, and improving patient education may all contribute to increased adherence and improved therapeutic efficacy for the general public. Company Analysis: Overview, Key Persons, Recent Developments, SWOT Analysis, Revenue Analysis Amgen Inc. Eli Lilly and Company F. Hoffmann La Roche AG GlaxoSmithKline Plc Merck & Co. Inc. Novartis AG Pfizer Inc. Teva Pharmaceutical Industries Ltd. UCB S.A. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $210.89 Million Forecasted Market Value (USD) by 2033 $308.84 Million Compound Annual Growth Rate 4.3% Regions Covered Saudi Arabia Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Saudi Arabia Osteoporosis Drugs Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Product Type6.2 By Route of Administration6.3 By States7. Product Type7.1 Bisphosphonates7.2 Calcitonin7.3 Rank Ligand Inhibitor7.4 Parathyroid Hormone Therapy (PTH)7.5 Selective Estrogen Receptor Modulators (SERMs)7.6 Sclerostin Inhibitor7.7 Others8. Route of Administration8.1 Oral8.2 Injectable8.3 Others9. Top States9.1 Dhahran9.2 Riyadh9.3 Khobar9.4 Jeddah9.5 Dammam9.6 Others10. Value Chain Analysis11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Competition11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threats13. Pricing Benchmark Analysis13.1 Amgen Inc.13.2 Eli Lilly and Company13.3 F. Hoffmann-La Roche AG13.4 GlaxoSmithKline Plc13.5 Merck & Co. Inc.13.6 Novartis AG13.7 Pfizer Inc.13.8 Teva Pharmaceutical Industries Ltd.13.9 UCB S.A.14. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Saudi Arabian Osteoporosis Drugs Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Epoch Times
3 hours ago
- Epoch Times
Eli Lilly Bribed Doctors to Prescribe Medications, Texas AG Alleges
Eli Lilly allegedly paid health care providers to recommend and prescribe weight loss drugs, according to a new complaint. An Eli Lilly program that makes available free nursing services to providers who prescribe the glucagon-like peptide-1 (GLP-1) medications illegally induces providers to prescribe the drugs, Texas Attorney General Ken Paxton said in a lawsuit filed on Aug. 12 in a district court in Harrison County.
